Spatial analysis reveals distinct immune phenotypes and tertiary lymphoid structure-like aggregates in pediatric acute myeloid leukemia

Joost B. Koedijk[1,2], Inge van der Werf[1], Marijn A. Vermeulen[1], Alicia Perzolli[1,2], Marta Fiocco[1,3,4], Hester A. de Groot-Kruseman[1], Rubina Moeniralam[1], Stefan Nierkens[1,5], Mirjam E. Belderbos[1], C. Michel Zwaan[1,2#], Olaf Heidenreich[1,6#]

[1]Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

[2]Department of Pediatric Oncology, Erasmus MC/Sophia Children's Hospital, 3015 GD Rotterdam, The Netherlands.

[3]Mathematical Institute, Leiden University, Leiden, The Netherlands

[4]Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.

[5]Center for Translational Immunology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.

[6]Wolfson Childhood Cancer Research Centre, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.

[#]Equal contribution

Abstract

Pediatric cancers are characterized by a relatively low mutational burden and therefore, children are thought to be poor candidates for T cell-engaging immunotherapies. Here, we performed a multidimensional characterization of the tumor immune microenvironment in newly diagnosed children with acute myeloid leukemia (AML) and non-leukemic controls. We identified a subset of pediatric AML patients with remarkably high levels of T cell infiltration and a relatively low abundance of anti-inflammatory macrophages. In addition, we detected large T cell networks that colocalized with B cells in the bone marrow of immune-infiltrated samples, resembling tertiary lymphoid structures as described in solid tumors. Using spatial transcriptomics, we dissected the composition of these structures and revealed unique hotspots of anti-tumor immunity. This work raises the possibility that a subset of pediatric AML patients may benefit from T cell-engaging immunotherapies and encourages further study of these lymphoid structures in the context of immunotherapy in AML.

Lead contacts: Joost B. Koedijk & Olaf Heidenreich, Princess Máxima Center for Pediatric

Oncology, 3584 CS Utrecht, The Netherlands. Phone: 088-9727272; E-mail:

j.b.koedijk@prinsesmaximacentrum.nl & o.t.heidenreich@prinsesmaximacentrum.nl

Running title: The spatial immune landscape of pediatric AML

Disclosure of conflicts of interest: The authors declare no financial conflicts of interest.

Keywords: spatial transcriptomics, digital spatial profiling, bone biopsy, secondary lymphoid

organs, ectopic, T cell networks, hematological malignancies, children.

A tumor microenvironment that is infiltrated by cytotoxic T cells is of crucial importance to elicit
a response to T cell-engaging immunotherapies such as immune checkpoint inhibitors and
bispecific antibodies (Bruni, Angell & Galon, 2020). In contrast, patients with an immune-
depleted or 'cold' tumor microenvironment show significantly reduced response rates. Due to
the relatively low mutational burden and the associated poor immunogenicity of pediatric
cancers, children are thought to be poor candidates for immunotherapy (Majzner et al., 2017;
Pfister et al., 2022). Among pediatric cancers, pediatric acute myeloid leukemia (AML) is a
cancer with a particularly low mutational burden (Gröbner et al., 2018). Nonetheless, recent
evidence suggests that considerable variation in immune cell infiltration exists among cancers
that are considered to be immunologically 'cold' (Dufva et al., 2020; Serroukh et al., 2023;
Daver et al., 2021). For instance, in adult AML, which has a relatively low mutational burden
in comparison to other adult cancer types, *TP53* mutations have been linked to relatively high
immune cell infiltration in the bone marrow (BM) and improved responses to immunotherapy
in comparison to *TP53*-WT adult AML (Gröbner et al., 2018; Dufva et al., 2020; Vadakekolathu
et al., 2020). However, little is known about the immune compartment in the BM of pediatric
AML patients and clinical trials that evaluate the efficacy of such therapies have only recently
been initiated for this population (Koedijk et al., 2021). Therefore, it is unclear whether children
with AML may be successfully treated with T cell-engaging immunotherapies. This prompted
us to perform a multidimensional characterization of the tumor immune microenvironment in
newly diagnosed children with *de novo* AML and non-leukemic controls. We identify a subset
of patients with remarkably high T cell infiltration in the BM, dissect the spatial immune
organization and specifically, unravel the composition of tertiary lymphoid structure-like
aggregates in the BM of AML, with implications for future immunotherapy approaches.

Results

A subset of pediatric AML patients has remarkably high T cell infiltration in the bone
marrow

For this study, we obtained 53 formalin-fixed and paraffin-embedded (FFPE) bone biopsies
from a representative cohort of pediatric patients with treatment-naïve *de novo* AML (n=43),
and from age- and sex-matched pediatric patients with treatment-naïve early-stage
rhabdomyosarcoma without evidence of malignancy infiltrating the BM (non-leukemic controls,
n=10; **Fig. 1A**). Patient characteristics are depicted in **Extended Data Table 1**. Using
immunohistochemistry (IHC), we found a decreased abundance of both the overall number of
T cells and cytotoxic T cells in pediatric AML patients in comparison to non-leukemic controls
(representative images are shown in **Fig. 1B-C**; two-sided $P = 0.006$ and $P = 0.003$,
respectively; **Fig. 1D-E**). However, the extent of overall T cell and cytotoxic T cell infiltration

could differ up to 90-fold between individual AML patients, with several patients showing

relatively high T cell infiltration in the BM. Because it has previously been shown that cancer

cells' genetic alterations may shape the tumor immune microenvironment, we assessed if

certain AML-associated genetic alterations were linked to the level of T cell infiltration

(Wellenstein & De Visser, 2018). Interestingly, most of the patients with relatively high T cell

infiltration in the BM had *KMT2A*-rearranged AML, the most common cytogenetic abnormality

in pediatric AML, although there was wide variation among this cytogenetic subgroup (De

Rooij, Zwaan & Van den Heuvel-Eibrink, 2015). In contrast, most other cytogenetic groups

showed low levels of both populations with little variation between patients, although several

outliers were seen in these groups as well (**Fig 1F-G**). Collectively, we identified substantial

variation in T cell infiltration in the BM of pediatric AML with a subset of patients showing a

remarkably high T cell frequency in the BM.

Immune infiltrated leukemias are characterized by tumor-specific T cell responses and

a relatively low abundance of anti-inflammatory macrophages

To further study pediatric AML patients with a relatively high T cell abundance in the BM, we

dichotomized patients into immune-infiltrated (n=8) and immune-depleted (n=35) groups using

the non-leukemic controls' median value of cytotoxic T cells as the cut-off value. Subsequently,

we performed immune-related gene expression profiling on a cytogenetically representative

subset of immune-infiltrated (n=5) and immune-depleted (n=18) samples. Among this subset,

four out of five (80%) immune-infiltrated samples had a KMT2A-rearrangement, while five out

of eighteen (28%) samples in the immune-depleted group had this cytogenetic abnormality

(**Extended Data Table 1**). First, we focused on cytotoxicity-related- and immune checkpoint

genes since their expression may give insight into the likelihood of response to immune

checkpoint inhibitors. In our cohort, immune-infiltrated patients showed upregulation of both

cytotoxic T cell genes (*CD8A*, *CD8B*) and cytotoxicity-related genes including *GZMK*,

suggestive of enrichment of GZMK$^+$ cytotoxic T cells, which has been associated with

response to PD-1 blockade in adult AML patients (**Fig. 2A**; Abbas et al., 2021). Moreover,

pediatric AML patients with an immune-infiltrated BM highly expressed *TNFRSF9* (encoding

CD137) and the immune checkpoint genes *PDCD1* (encoding PD-1), *CTLA4*, *TIGIT* and

LAG3, indicative of tumor-specific T cell responses that may be successfully reinvigorated by

ICIs (Ye et al., 2014; Philip & Schietinger, 2022; **Fig. 2A**). Importantly, using a publicly

available pediatric AML scRNAseq dataset, we confirmed that the above-mentioned

checkpoint genes are mainly expressed by cytotoxic T cells, and that *TIGIT* and *LAG3* were

the most widely expressed among this population (n=8 patients; Bailur et al., 2020; **Extended**

Data Fig. 1A-E). Taken together, these results suggest that pediatric AML patients with an

immune-infiltrated BM may show increased responses to immune checkpoint inhibitors in

comparison to patients with an immune-depleted BM, and that the immune checkpoints TIGIT

and LAG-3 may prove suitable targets to enhance cytotoxic T cell function in pediatric AML.

We next investigated whether we could identify differences in factors that either

promote or restrict T cell infiltration in the BM. As anticipated, immune-infiltrated samples had

significantly higher expression of genes related to T cell-attracting chemokines (*CXCL9*,

CXCL10), and their corresponding receptor (*CXCR3*; **Fig. 2A**). In line with this, pathway

analysis using GO biological processes indicated that immune-infiltrated samples were

enriched in T cell migratory and -chemotaxis pathways, suggesting that immune-depleted

samples are devoid of signals that attract T cells to the BM (**Fig. 2B**). From solid cancers, we

know that macrophages in the tumor microenvironment are the main regulators of the extent

of T cell infiltration into the tumor (House et al., 2020; Hoch et al., 2022). Specifically, pro-

inflammatory, M1-like macrophages are known to be the primary source of T cell-attracting

chemokines, while anti-inflammatory, M2-like macrophages restrict T cell infiltration into the

tumor (Italiani & Boraschi, 2014; Joyce & Fearon, 2015). Previously, a specific M2-like

macrophage signature has been generated for five cancer types including AML and therefore,

we investigated the abundance of M2-like macrophages in our pediatric AML cohort (Jiang et

al., 2018). Interestingly, the estimated abundance of M2-like macrophages was inversely

correlated with both the total T cell and cytotoxic T cell frequency in the BM (Spearman's r = -

0.76 [95% CI: -0.89 to -0.51], $P < 0.001$, r = -0.64 [95% CI: -0.83 to -0.30], $P = 0.001$,

respectively; **Fig. 2C** and **Extended Data Fig. 1F**). In line with this, we identified a significantly

decreased M2-like macrophage abundance in immune-infiltrated samples compared to

immune-depleted samples (two-sided $P < 0.001$; **Fig. 2D**). Notably, immune-depleted samples

had significantly higher expression of the gene encoding arginase type II (*ARG2*), which is

known to be crucial for AML blast-mediated polarization of monocytes into an M2-like

phenotype (Mussai et al., 2013). Next, because it is unknown whether the abundance of M2-

like macrophages affects the response to T cell-engaging immunotherapies in AML, we

investigated whether the M2-like macrophage abundance is associated with poor response

upon these therapies. However, pre-treatment gene expression data from immunotherapy-

treated pediatric AML patients were not available and therefore, we used an immune-related

gene expression profiling dataset of pre-treatment BM samples from 30 refractory or relapsed

adult AML patients that were treated with flotetuzumab, a bispecific CD3 x CD123 antibody,

in the context of a clinical trial (CP-MGD006-01; NCT02152956; obtained from Vadakekolathu

et al., 2020). Interestingly, the M2-like macrophage abundance was significantly lower in

patients with anti-leukemic activity (n=12) in comparison to non-responders (n=18; two-sided

$P < 0.001$; **Fig. 2E**). In fact, the M2-like macrophage abundance outperformed several other

known predictors of response to immunotherapy (area under the receiver operating

characteristic-curve: 0.852 [95% CI 0.71-0.99], *P* = 0.0012; **Fig. 2F**; Jiang et al., 2018, Ayers

et al., 2017). In summary, we identified a relatively low abundance of M2-like macrophages in

immune-infiltrated samples. In addition, we found that the M2-like macrophage abundance in

the BM could be used as a potential biomarker for response to T cell-engaging

immunotherapies in AML.

T cells cluster into spatially organized networks in the bone marrow of pediatric AML

Intriguingly, IHC performed to quantify the T cell infiltration in the BM revealed large networks

of T cells in immune-infiltrated samples. Previously, it has been shown in mice that circulating

naïve T cells home to the BM upon intravenous antigen administration, where they form dense

networks of T cells and subsequently, are activated and differentiated towards effector and

memory cells (Feuerer et al., 2003). Therefore, we investigated the spatial organization of T

cells in pediatric immune-infiltrated, immune-depleted, and non-leukemic BM samples. T cell

networks were defined as at least 10 directly interacting T cells (≤10 μm between adjacent

nuclei), to minimize the chance of classifying randomly dispersed T cells as networks (Gaglia

et al., 2022; **Fig. 3A**). Interestingly, T cell networks were detected in both AML groups and in

controls, although significantly more frequent in immune-infiltrated samples compared to

immune-depleted samples (*P* < 0.001; **Fig. 3B** and **Extended Data Table 2**). In fact, there

was a strong correlation between the level of T cell infiltration and the number of T cell

networks, albeit two out of eight immune-infiltrated patients had a relatively low number of

networks (n=53; *r* = 0.86 [95% CI: 0.77-0.92], *P* < 0.001; **Fig. 3C**). Also, immune-infiltrated

samples showed a trend towards having larger networks versus immune-depleted samples

(*P*=0.086; **Fig. 3D**). Remarkably, we noticed that in the BM of immune-infiltrated samples with

a multitude of large networks (>100 T cells), T cell network areas were largely devoid of AML

cells, which could indicate local clearance of AML cells (determined using AML

immunophenotypic markers; Pospori et al., 2020; **Fig. 3E-F**). In contrast, we did not identify

such large T cell networks in the BM of immune-depleted samples (**Fig. 3G-H**). Taken

together, these data show that spatially organized networks of T cells are widely abundant in

pediatric AML patients with an immune-infiltrated BM, potentially reflecting local priming of

anti-tumor immunity and/or immune-mediated elimination of AML cells.

Spatial transcriptomics reveals localized cellular and humoral immunity in *KMT2A*-
rearranged patients

Subsequently, we wondered whether these large T cell networks in the BM resemble

secondary lymphoid organ-like structures, as seen in solid cancers ('tertiary lymphoid

structures', TLSs; Schumacher & Thommen, 2022). First, we checked whether T cells

colocalized with CD20⁺ B cells, since both T and B cells are the main components of secondary

lymphoid organs (Ruddle & Akirav, 2009). Indeed, in four immune-infiltrated pediatric AML BM

samples, we detected large aggregates composed of T- and B cells ('lymphoid aggregates';
defined as networks of at least 100 directly interacting T cells that colocalized with a dense
core of CD20$^+$ B cells). Interestingly, all four patients had *KMT2A*-rearranged AML.
Importantly, these lymphoid aggregates were not classified as malignant upon pathological
examination (Maccio et al., 2022). In fact, these aggregates had a non-trabecular localization,
did not contain cells with atypical morphology, and showed a predominance of CD3$^+$ T cells,
all features that have been associated with benign BM lymphoid aggregates (Maccio et al.,
2022). In immune-depleted and non-leukemic control samples, we did not detect such
lymphoid aggregates. Moreover, in solid cancers, TLSs arise in the context of chronic
inflammation (Schumacher & Thommen, 2022), which may also have driven the formation of
lymphoid aggregates in the BM of immune-infiltrated samples. To test whether lymphoid
aggregates in the BM of pediatric AML patients represent structures similar to TLSs, we
performed spatial transcriptomics using the GeoMx platform on bone biopsy tissue of two
KMT2A-rearranged patients that had an immune-infiltrated BM with lymphoid aggregates
(Merritt et al., 2020; **Fig. 4A-B**). As a control, we used tissue of one *KMT2A*-rearranged patient
with an immune-infiltrated BM but without these aggregates (**Fig. 4C**). In total, we successfully
sequenced 94 regions: (1) regions that contained lymphoid aggregates (n=20), (2) regions
with T cell networks (n=26), and (3) regions that consisted of a mixture of AML-, T-, and B
cells ('mixed' regions; n=48). Then, we explored which regions expressed TLS-associated
genes using a previously generated TLS-signature (Meylan et al., 2022; **Fig. 4A-C**). In
general, we observed concordant enrichment of the TLS-signature in areas we designated as
regions containing lymphoid aggregates and hence, termed these structures 'TLS-like
aggregates' (**Fig. 4A-B**). Surprisingly, one region in the biopsy without lymphoid aggregates
was heavily enriched for the TLS-signature, possibly reflecting a forming or disintegrating TLS-
like aggregate (**Fig. 4C**).

We next used *SpatialDecon*, a deconvolution approach optimized for spatial
transcriptomic data, to examine the abundance of multiple immune and stromal cell types in
these TLS-like aggregates (Danaher et al., 2022). To this end, we used safeTME, a scRNA-
seq and flow-sorted bulk RNA-seq based reference profile of microenvironmental cell
populations (Danaher et al., 2022). Importantly, the similarity in cellular composition identified
using unsupervised hierarchical clustering (Euclidian distance; complete linkage) was highly
concordant with our IHC-based distinction between regions (**Fig. 5A**). Interestingly, TLS-like
aggregate regions and T cell networks both showed a significantly higher abundance of
memory cytotoxic T cells, potentially because of local cytotoxic T cell priming (Philip &
Schietinger, 2022; **Fig. 5B**). However, both types of regions also had a significantly higher
abundance of Tregs, which may be a limiting factor of anti-tumor immunity (Joshi et al., 2015;

Fig. 5C). Because of this colocalization of cytotoxic T cells with Tregs, we interrogated the
functional state of cytotoxic T cells using an additional scRNAseq reference profile specific for
activated and resting BM T cells (Danaher et al., 2022). TLS-like aggregate regions not only
had a significantly higher abundance of both activated and resting cytotoxic T cells, but also
showed the highest ratio of activated to resting cytotoxic T cells in comparison to T cell
network- and mixed regions (mean ratio of 0.72, 0.68, and 0.55, respectively), suggesting that
cytotoxic T cells in TLS-like aggregates are present in an activated state despite the presence
of Tregs (**Fig. 5D-E** & **Extended Data Fig. 2B**). Furthermore, the relatively high number of
activated T cells may explain the absence of AML cells in these areas. In contrast to the T cell
compartment, TLS-like aggregate regions had a significantly higher abundance of all
measured B cell populations in comparison to mixed- and T cell network regions (**Fig. 5F-H**).
Notably, differential gene expression analysis between TLS-like aggregate and mixed regions
showed upregulation of genes indicative of immunoglobulin class-switching (*IGHG3*, *IGHG4*,
IGHA1; **Extended Data Fig. 2A**). Also, we confirmed the enrichment of plasma and/or
memory B cells in TLS-like aggregate regions using IHC, together suggesting anti-tumor
antibody production in TLS-like aggregate regions (**Fig. 5I**; Akkaya et al., 2020). Other critical
components of the TLSs seen in solid cancers are dendritic cells because of their pivotal role
in priming of the immune response (Schumacher & Thommen, 2022). Interestingly, myeloid
but not plasmacytoid dendritic cells were significantly enriched in TLS-like aggregate regions
in comparison to mixed regions (**Fig. 5I** & **Extended Data Fig. 2C**). Furthermore,
macrophages were significantly enriched in TLS-like aggregate and T cell network regions in
comparison to mixed regions, which we validated using IHC (**Fig. 5J&M**). Specifically, TLS-
like aggregates and T cell network regions showed a modest decrease in the abundance of
M2-like macrophages compared to mixed regions, suggesting that the M1-like macrophage
abundance was increased in TLS-like aggregate and T cell network regions (**Fig. 5K**). In
contrast, neutrophils had a significantly higher abundance in mixed regions (**Extended Data**
Fig. 2D). Collectively, these results suggest that *KMT2A*-rearranged pediatric AML patients
with an immune-infiltrated BM may harbor spatially organized areas of cellular and humoral
anti-tumor immunity in the BM, which may translate to a positive effect on response upon T
cell-engaging immunotherapies (Schumacher & Thommen, 2022).

Discussion

Pediatric cancers are characterized by a relatively low mutational burden and therefore,
children are thought to be poor candidates for T cell-engaging immunotherapies (Majzner et
al., 2017; Pfister et al., 2022). This prompted us to perform a multidimensional characterization
of the tumor immune microenvironment in newly diagnosed children with *de novo* AML and
non-leukemic controls. We identified a subset of patients with remarkably high T cell infiltration

in the BM, dissected the spatial organization of the immune compartment, and for the first
time, unraveled the composition of TLS-like aggregates in the BM of AML.

Despite the relatively low mutational burden and the associated poor immunogenicity
of pediatric cancers, previous work has shown that considerable variation in immune cell
infiltration exists in cancers that are considered to be immunologically 'cold' (Gröbner et al.,
2018; Dufva et al., 2020). Indeed, we observed wide variation in T cell infiltration in the BM of
pediatric AML patients, including a subset that had remarkably high levels of T cell infiltration.
These immune-infiltrated samples showed gene expression suggestive of an enrichment of
GZMK[+] cytotoxic T cells, which has been associated with response to immune checkpoint
blockade in adult AML patients (Abbas et al., 2021). Hence, pediatric AML patients with an
immune-infiltrated BM may show increased responses to immune checkpoint inhibitors in
comparison to patients with an immune-depleted BM. Specifically, the immune checkpoint
receptor genes *TIGIT* and *LAG3* were the most upregulated immune checkpoint genes in
immune-infiltrated patients, suggesting that these less conventional checkpoint receptors may
prove interesting immunotherapeutic targets in pediatric AML (Bailur et al., 2020; Lasry et al.,
2022; Penter et al., 2023). Furthermore, we identified that immune-infiltrated samples
harbored a significantly lower abundance of the immunosuppressive M2-like macrophages in
comparison to immune-depleted samples. Therefore, repolarizing M2-like macrophages
towards an M1-like phenotype could be a suitable immunotherapeutic option in pediatric AML
patients with an immune-depleted BM (Duan & Luo, 2021; Li et al., 2022). Of interest, a recent
study indicated that M2-like macrophages in the BM of adult AML patients showed increased
expression of the immune checkpoints TIGIT and LAG-3 compared to healthy donors, and
that TIGIT blockade was able to repolarize these M2-like macrophages to an M1-like
phenotype (Brauneck et al., 2022). Thus, TIGIT and LAG-3 blockade may have beneficial
effects on both the T cell and macrophage compartment, which encourages further evaluation
of these agents in the preclinical setting.

In solid cancers, the importance of the spatial component of the immune response is
widely recognized. For instance, in the so-called 'excluded' tumors, an immune response is
triggered but not able to invade the tumor bed and hence, associates with poor response to
immunotherapy (Bruni, Angell & Galon, 2020). In hematological malignancies, the spatial
organization of the immune response is understudied, while potentially critical to the success
of immunotherapeutic interventions. In our study, we identified large aggregates of T- and B
cells in the leukemic BM that resembled gene expression characteristics of TLSs (Meylan et
al., 2022). Importantly, pathology examination indicated that the TLS-like aggregates detected
in immune-infiltrated pediatric AML samples in our cohort were not of malignant origin. In fact,
these aggregates likely arose because of the chronically inflamed tumor microenvironment,

as seen with TLSs in solid cancers (Schumacher & Thommen, 2022). In line with this, we did
not detect TLS-like aggregates in the immune-depleted or non-leukemic control samples.
Furthermore, we dissected the composition of these TLS-like aggregates in the BM of pediatric
AML patients, which turned out to be local hotspots of activated cytotoxic T cells, memory B
cells, and plasma cells. Moreover, these hotspots were largely devoid of AML cells despite
full-blown leukemia in other areas of the BM. Hence, these data suggest the presence of
localized anti-tumor immunity in the BM of AML, which may have profound implications for
future immunotherapy approaches. For instance, the increased abundance of plasma cells
and the expression of class-switched immunoglobulin genes suggest the production of anti-
tumor antibodies, which may lead to novel targets for antibody-based therapies through
identification of the respective target antigens (Fridman et al., 2022). Likewise, the presence
of TLS-like aggregates in AML may pave the way for new adoptive cell therapies with tumor-
infiltrating T cells, since the T cells primed in these structures are likely to be tumor-reactive
(Schumacher & Thommen, 2022). Current immunotherapies may also release the breaks of
TLS-like aggregate-associated anti-tumor immunity, as illustrated by the results of a recent
clinical trial in advanced soft-tissue sarcoma which showed that patients enrolled based on
the presence of TLSs had an overall response rate of 30% to PD-1 blockade, opposed to 2.4%
in an unselected cohort (Italiano et al., 2022).

Remarkably, all four patients with TLS-like aggregates in the BM had a *KMT2A*-
rearrangement. Although we detected wide variation in T cell infiltration in patients with this
cytogenetic alteration, the detection of these aggregates in patients with *KMT2A*-rearranged
AML indicates that at least some of these patients, which have relatively poor outcomes upon
chemotherapy, may be good candidates for immunotherapy (Van Weelderen et al., 2020). In
conclusion, our results suggest the presence of distinct immune phenotypes in the BM of
patients with pediatric AML including the presence of TLS-like aggregates in *KMT2A*-
rearranged AML, suggesting that a subset of children with AML may benefit from T cell-
engaging immunotherapies, and which encourages further study of these lymphoid structures
in the BM in the context of immunotherapy in AML.

Online methods

Ethical regulation

This study complies with all relevant ethical regulations and was approved by the Institutional
Review Board of the Princess Máxima Center for Pediatric Oncology (PMCLAB2021.207 &
PMCLAB2021.238) and the Scientific Committee of the Dutch Nationwide Pathology
Databank (PALGA: lzv2021-82; Casparie et al., 2007). All patients treated at the Princess
Máxima Center provided written consent for banking and research use of these specimens,

according to the Declaration of Helsinki. Bone biopsy tissues acquired from external biobanks
(n=28) were leftover material from standard care procedures and therefore, no informed
consent was acquired, according to Dutch legislation and the code of conduct of the
Committee on Regulation of Health Research (COREON).

Human patient samples

FFPE bone biopsies taken from the crista of children with treatment-naïve *de novo* AML were
obtained from the Princess Máxima Center Biobank (n=15) and biobanks of 10 other Dutch
hospitals (n=28), mediated by the Dutch National Tissue Portal. As controls, FFPE bone
biopsies of age- and sex-matched children with treatment-naïve early-stage
rhabdomyosarcoma were obtained from the Princess Máxima Center Biobank (n=10; non-
leukemic controls). An experienced hemato-onco pathologist confirmed that these control
biopsies resembled normal hematopoiesis and that there was no malignancy infiltrating the
BM.

Immunohistochemistry staining and digital image analysis

Bone biopsies were cut into consecutive 4 μm sections and stained with hematoxylin and
eosin (H&E). Conventional IHC was performed for CD3, CD3-CD4 (duplex), CD8, CD20,
CD34, CD117, CD15, and IgM-IgG (duplex) using a Ventana Benchmark Ultra (Roche, Basel,
Switzerland) automated staining instrument according to manufacturers' recommendations. A
list of antibodies and suppliers is available in **Extended Data Table 3**. Digital scans of stained
slides were obtained using a NanoZoomer scanner (Hamamatsu, Shizuoka, Japan). On 4 μm
sections from three *KMT2A*-rearranged pediatric AML patients with an immune-infiltrated BM,
we applied the FixVUE APC[TM] Kit (Ultivue Inc. Cambridge, MA, USA; CD20, CD68/CD163
cocktail, CD11c, and MHC-II) using the antibody conjugated DNA-barcoded multiplexed
immunofluorescence method, as previously described (Manesse et al., 2020). The staining
was performed on the BOND RX (Leica Biosystems, Wetzlar, Germany). To acquire an H&E
staining on the same slide, the fluorescently labelled slides were soaked in PBS until the
coverslips could be removed, and a standard H&E stain was performed using an Epredia
Gemini (Epredia, Portsmouth, UK). Digital immunofluorescence and brightfield images were
scanned on a Zeiss Axioscan Z1 (ZEISS, Oberkochen, Germany) and stacked with Ultivue's
UltiStacker software. Whole-slide digital image analysis was performed in QuPath (V.0.3.2,
Bankhead et al., 2017). Inside QuPath, the deep learning-based cell segmentation tool
StarDist and the machine learning-based Random Trees classifier were used to quantify the
number of positive cells per mm^2 (Schmidt et al., 2018). T cell networks were defined as at
least 10 directly interacting CD3[+] T cells (≤ 10 μm between adjacent nuclei), detected using
Delaunay Triangulation, and normalized per 10 cm^2 (Delaunay, 1934; Gaglia et al., 2022).

Large T cell networks of at least 100 directly interacting T cells that colocalized with a dense
core of CD20⁺ B cells were classified as lymphoid aggregates.

Immune-related gene expression profiling

Four consecutive sections of 10 µm from 5 immune-infiltrated and 18 immune-depleted FFPE
bone biopsies (the non-leukemic controls' median value of cytotoxic T cells was used as the
cut-off value) from a cytogenetically representative cohort of pediatric AML patients were used
to isolate RNA and to perform immune-related gene expression profiling with the 770-gene
PanCancer IO 360 panel, as previously described (Danaher et al., 2017; Vadakekolathu et al.,
2020; NanoString, Seattle, WA, USA). After passing quality control, raw data were normalized
using ROSALIND® according to Nanostring's recommendations (https://rosalind.bio/; San
Diego, CA, USA). Normalized data were uploaded to the online iDEP platform and differentially
expressed genes between immune-infiltrated and immune-depleted samples were identified
using *DEseq2* with a false-discovery rate (FDR) cut-off of 0.05 and a minimum fold change of
2 (integrative Differential Expression and Pathway analysis;
http://bioinformatics.sdstate.edu/idep96/; V.0.96; Ge, Son & Yao, 2018). Pathway analysis
was performed using parametric gene set enrichment analysis with the GO Biological
Processes gene set with an FDR of 0.05 (Ashburner et al., 2000; The Gene Ontology
Consortium, 2020). The abundance of M2-like macrophages was estimated using a published
gene signature of M2-like macrophages compared to M1-like macrophages, inside the TIDE
environment (tide.dfci.harvard.edu/; Beyer et al., 2020; Jiang et al., 2018). Similarly, the T cell
inflamed gene expression profile, the CD8-, IFN-γ-, and TIDE scores were all calculated using
TIDE.

GeoMx Digital Spatial Profiling

5 µm thick FFPE bone biopsy sections from three *KMT2A*-rearranged pediatric AML patients
with an immune-infiltrated BM were placed on the same slide and prepared for GeoMx Digital
Spatial Profiling (DSP; NanoString), as previously described (Merritt et al., 2020). Slides were
simultaneously incubated with immunofluorescent antibodies and GeoMx Whole
Transcriptome Atlas profiling reagents. SYTO13 (S7575, Thermo Fisher,) was used for
identification of nuclei, CD45 (NBP2-34528, Novus) for leukocytes, and CD3 (NBP2-
54392AF647, Novus) for T cells. Stained slides were loaded onto the GeoMx instrument and
scanned. Regions of interest (ROIs) were selected using the above-mentioned antibodies in
combination with overlayed images of CD20, CD34, CD3-CD4 (duplex), and CD117 (IHC).
Then, UV-photocleaved oligonucleotides were collected in separate wells and sequenced on
the Nextseq2000 (Illumina, San Diego, CA, USA). In total, we successfully sequenced 94
regions (one failed quality control) with on average 273 cells per region (range: 156 to 778

cells). Raw data were normalized using Quartile 3 count (Q3) normalization in R (V.4.2.1) as
per NanoString's recommendations (code is available in the vignette of the *Geomxtools*
package). The expression of the TLS-signature as described by Meylan et al. was plotted in
R on the scanned image using *SpatialOmicsOverlay* (Meylan et al., 2022). Spatial
Deconvolution was performed in the GeoMx DSP Analysis Suite using both the safeTME and
healthy adult BM T cell reference profiles (*SpatialDecon* package; cell reference profiles are
available via https://github.com/Nanostring-Biostats/CellProfileLibrary; Danaher et al., 2022).
Differential gene expression analysis between regions was performed using a linear mixed-
effects model including random slope to correct for the fact that multiple regions come from
the same biopsy, and the FDR method (code: *Geomxtools* package; minimum fold change of
2).

External pediatric and adult AML datasets

Single-cell RNA-sequencing (scRNAseq) data from 8 newly diagnosed pediatric AML patients
were re-analyzed for cell-type specific *PDCD1*, *CTLA4*, *TIGIT*, and *LAG3* expression using
the Tumor Immune Single-cell Hub (Bailur et al., 2020; Sun et al., 2021). Immune-related gene
expression data (PanCancer IO 360 panel) from pre-treatment BM samples from 30 relapsed
or refractory adult AML patients that were treated with flotetuzumab in the context of the CP-
MGD006-01 clinical trial (NCT02152956) were kindly provided by Professor Sergio Rutella
(Nottingham Trent University, England) and dr. Patrick Kaminker (MacroGenics, Rockville,
MD, USA) and analyzed as described above.

Statistical analyses

Statistical analyses were performed with GraphPad Prism V.9.3.0 (GraphPad Software, LA
Jolla, CA, USA). Differences between two independent groups were compared using the
Mann-Whitney test. The correlation between two variables was evaluated using Spearman's
r. To measure the area under the receiver operating characteristic curve, we employed the
Wilson-Brown method. In case of multiple comparisons and no Gaussian distribution of
residuals, we employed the Kruskal-Wallis test followed by Dunn's test for multiple
comparisons including a Bonferroni correction. Hence for the multiple testing, $P<0.01$ was
considered statistically significant in these comparisons. For all the other comparisons, $P<0.05$
was considered statistically significant.

Data availability

428 Sequencing data can be accessed from the Gene Expression Omnibus (nCounter data:
429 GSEXXX; GeoMx data: GSEXXX; both normalized counts) and from the European Genome-

430 phenome Archive (EGA) database (https://ega-archive.org/studies/EGAXXX; raw nCounter
431 and GeoMx data).

Acknowledgements

We would like to thank the staff of the University Medical Center Utrecht Tissue Facility for
their excellent immunohistochemistry service (Domenico Castigliego, Petra van der Weide,
Petra van der Kraak, Karina Timmer, Sven van Kempen), and the team at Utrecht Sequencing
Facility for performing the NanoString experiments (nCounter and GeoMx) and for providing
assistance with data-analysis (dr. Ies Nijman, Robin Geene, Pim Kloosterman). We are
grateful to Professor Sergio Rutella (Notthingham Trent University) and dr. Patrick Kaminker
(MacroGenics) for providing us with immune-related gene expression data from
immunotherapy-treated adult AML samples. Dr. Ivette Deckers and dr. Annette Gijsbers
(PALGA) performed essential work for the acquisition of bone biopsies from other hospitals.
From the Princess Máxima Center for Pediatric Oncology, prof. dr. Gertjan Kaspers and dr.
Bianca Goemans aided with identifying potential patients, the biobank staff (Jantien Woudstra,
Marion Koopmans, dr. Edwin Sonneveld) helped to identify patient material, and Arie Maat
aided with the sectioning of bone biopsy sections. Also, we would like to thank dr. Caroline
Lindemans, members from the Heidenreich group (dr. Katarzyna Szoltysek, dr. Farnaz
Barneh, dr. Mauricio Ferrao-Blanco, Elizabeth Schweighart, Nina van der Wilt), the Van
Heesch group (dr. Ana Pinheiro-Lopes), and the single-cell sequencing facility (dr. Lindy
Visser) at the Princess Máxima Center for Pediatric Oncology for carefully reading the
manuscript and/or fruitful discussions. This work has been funded in part by a KIKA (329)
program grant to O.H. Figure 1A and 3A have been created using BioRender.com.

Author contributions

453 Conceptualization: J.B.K, I.W., M.A.V., S.N., M.B., C.M.Z., O.H. Methodology: J.B.K, I.W.,
454 M.A.V., M.F., S.N., M.B., C.M.Z., O.H. Data acquisition: J.B.K., M.A.V., H.G.-K., R.M. Data
455 analysis and interpretation: J.B.K., I.W., A.P. Writing – Original Draft: J.B.K.; Writing –
456 Reviewing & Editing: all authors; Supervision: S.N., M.B., C.M.Z., O.H.

Koedijk et al.

References

Abbas HA, Hao D, Tomczak K, et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. *Nat Commun.* 2021;12(1):6071.

Akkaya M, Kwak K, Pierce SK. B cell memory: building two walls of protection against pathogens. *Nat Rev Immunol.* 2020;20(4):229-238.

Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet.* 2000;25(1):25-29.

Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. *J Clin Invest.* 2017;127(8):2930-2940.

Bailur JK, McCachren SS, Pendleton K, et al. Risk-associated alterations in marrow T cells in pediatric leukemia. *JCI Insight.* 2020;5(16):e140179.

Bankhead P, Loughrey MB, Fernández JA, et al. QuPath: Open source software for digital pathology image analysis. *Sci Rep.* 2017;7(1):16878.

Beyer M, Mallmann MR, Xue J, et al. High-resolution transcriptome of human macrophages. *PLoS One.* 2012;7(9):e45466.

Brauneck F, Fischer B, Witt M, et al. TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis. *J Immunother Cancer.* 2022;10(12):e004794.

Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. *Nat Rev Cancer.* 2020;20(11):662-680.

Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. *Cell Oncol.* 2007;29(1):19-24.

Danaher P, Warren S, Dennis L, et al. Gene expression markers of Tumor Infiltrating Leukocytes. *J Immunother Cancer.* 2017;5:18.

Danaher P, Kim Y, Nelson B, et al. Advances in mixed cell deconvolution enable quantification of cell types in spatial transcriptomic data. *Nat Commun.* 2022;13(1):385

Daver N, Alotaibi AS, Bücklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. *Leukemia.* 2021;35(7):1843-1863.

Delaunay B. Sur la sphère vide. *Bull. Acad. Sci. URSS.* 1934:793–800.

de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: From Biology to Clinical Management. *J Clin Med.* 2015;4(1):127-149.

Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. *Signal Transduct Target Ther.* 2021;6(1):127.

Dufva O, Pölönen P, Brück O, et al. Immunogenomic Landscape of Hematological Malignancies. *Cancer Cell.* 2020;38(3):380-399.e13.

Feuerer M, Beckhove P, Garbi N, et al. Bone marrow as a priming site for T-cell responses
to blood-borne antigen. *Nat Med*. 2003;9(9):1151-1157.

Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Sautès-Fridman C. B cells and
tertiary lymphoid structures as determinants of tumour immune contexture and clinical
outcome. *Nat Rev Clin Oncol*. 2022;19(7):441-457.

Gaglia G, Burger M, Ritch CC, et al. Lymphocyte networks are dynamic communities in the
immunoregulatory landscape of lung adenocarcinoma. *bioRxiv*. 2022-08.

Ge SX, Son EW, Yao R. iDEP: an integrated web application for differential expression and
pathway analysis of RNA-Seq data. *BMC Bioinformatics*. 2018;19(1):534.

Gene Ontology Consortium. The Gene Ontology resource: enriching a GOld mine. *Nucleic
Acids Res*. 2021;49(D1):D325-D334.

Gröbner SN, Worst BC, Weischenfeldt J, et al. The landscape of genomic alterations across
childhood cancers. *Nature*. 2018;555(7696):321-327.

Hoch T, Schulz D, Eling N, Gómez JM, Levesque MP, Bodenmiller B. Multiplexed imaging
mass cytometry of the chemokine milieus in melanoma characterizes features of the
response to immunotherapy. *Sci Immunol*. 2022;7(70):eabk1692.

House IG, Savas P, Lai J, et al. Macrophage-Derived CXCL9 and CXCL10 Are Required for
Antitumor Immune Responses Following Immune Checkpoint Blockade. *Clin Cancer Res*.
2020;26(2):487-504.

Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional
Differentiation. *Front Immunol*. 2014;5:514.

Italiano A, Bessede A, Pulido M, et al. Pembrolizumab in soft-tissue sarcomas with tertiary
lymphoid structures: a phase 2 PEMBROSARC trial cohort. *Nat Med*. 2022;28(6):1199-1206.

Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer
immunotherapy response. *Nat Med*. 2018;24(10):1550-1558.

Joshi NS, Akama-Garren EH, Lu Y, et al. Regulatory T Cells in Tumor-Associated Tertiary
Lymphoid Structures Suppress Anti-tumor T Cell Responses. *Immunity*. 2015;43(3):579-590.

Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment.
Science. 2015;348(6230):74-80.

Koedijk JB, van der Werf I, Calkoen FG, et al. Paving the Way for Immunotherapy in
Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward. *Cancers
(Basel)*. 2021;13(17):4364.

Lasry A, Nadorp B, Fornerod M, et al. An inflammatory state remodels the immune
microenvironment and improves risk stratification in acute myeloid leukemia. *Nat Cancer*.
2023;4(1):27-42.

Li W, Wang F, Guo R, Bian Z, Song Y. Targeting macrophages in hematological
malignancies: recent advances and future directions. *J Hematol Oncol*. 2022;15(1):110.

Maccio U, Rets AV. Lymphoid aggregates in bone marrow: a diagnostic pitfall. *J Clin Pathol*.
2022;75(12):807-814.

Majzner RG, Heitzeneder S, Mackall CL. Harnessing the Immunotherapy Revolution for the
Treatment of Childhood Cancers. *Cancer Cell.* 2017;31(4):476-485.

Manesse M, Patel KK, Bobrow M, Downing SR. The InSituPlex® Staining Method for
Multiplexed Immunofluorescence Cell Phenotyping and Spatial Profiling of Tumor FFPE
Samples. *Methods Mol Biol.* 2020;2055:585-592.

Merritt CR, Ong GT, Church SE, et al. Multiplex digital spatial profiling of proteins and RNA
in fixed tissue. *Nat Biotechnol.* 2020;38(5):586-599.

Meylan M, Petitprez F, Becht E, et al. Tertiary lymphoid structures generate and propagate
anti-tumor antibody-producing plasma cells in renal cell cancer. *Immunity.* S2022;55(3):527-
541.e5.

Mussai F, De Santo C, Abu-Dayyeh I, et al. Acute myeloid leukemia creates an arginase-
dependent immunosuppressive microenvironment. *Blood.* 2013;122(5):749-758.

Penter L, Liu Y, Wolff JO, et al. Mechanisms of response and resistance to combined
decitabine and ipilimumab for advanced myeloid disease. *Blood.* 2023;blood.2022018246.

Pfister SM, Reyes-Múgica M, Chan JKC, et al. A Summary of the Inaugural WHO
Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era.
Cancer Discov. 2022;12(2):331-355.

Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. *Nat Rev*
Immunol. 2022;22(4):209-223.

Ruddle NH, Akirav EM. Secondary lymphoid organs: responding to genetic and
environmental cues in ontogeny and the immune response. *J Immunol.* 2009;183(4):2205-
2212.

Schmidt U, Weigert M, Broaddus C et al. Cell detection with star-convex polygons.
International Conference on Medical Image Computing and Computer-Assisted Intervention.
2018;265-273.

Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. *Science.*
2022;375(6576):eabf9419.

Serroukh Y, Hébert J, Busque L, et al. Blasts in context: the impact of the immune
environment on acute myeloid leukemia prognosis and treatment. *Blood Rev.*
2023;57:100991.

Sun D, Wang J, Han Y, et al. TISCH: a comprehensive web resource enabling interactive
single-cell transcriptome visualization of tumor microenvironment. *Nucleic Acids Res.*
2021;49(D1):D1420-D1430.

Vadakekolathu J, Lai C, Reeder S, et al. TP53 abnormalities correlate with immune
infiltration and associate with response to flotetuzumab immunotherapy in AML. *Blood Adv.*
2020;4(20):5011-5024.

Vadakekolathu J, Minden MD, Hood T, et al. Immune landscapes predict chemotherapy
resistance and immunotherapy response in acute myeloid leukemia. *Sci Transl Med.*
2020;12(546):eaaz0463.

Koedijk et al.

Van Weelderen RE, Klein K, Goemans BF et al. Outcomes of (novel) subgroups in 1257
pediatric patients with KMT2A-rearranged acute myeloid leukemia (AML) and the
significance of minimal residual disease (MRD) status: A retrospective study by the I-BFM-
SG. *Blood*. 2020;136:26-27.

Wellenstein MD, de Visser KE. Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor
Immune Landscape. *Immunity*. 2018;48(3):399-416.

Ye Q, Song DG, Poussin M, et al. CD137 accurately identifies and enriches for naturally
occurring tumor-reactive T cells in tumor. *Clin Cancer Res*. 2014;20(1):44-55.

Figure Legends

Figure 1. Spatial analysis of the bone marrow immune microenvironment in pediatric
AML and non-leukemic controls.

(A) Schematic overview of the study population, used techniques, and the digital image
analysis pipeline. (B-C) Representative bone biopsy images acquired from a treatment-naïve
pediatric AML patient (B) and non-leukemic control (C) showing H&E staining, CD3[+] T cells
(CD3 in brown), and CD8[+] T cells (CD8 in brown). White lobules indicate adipocytes. (D-E)
Comparison of the normalized abundance of CD3[+] T cells (D) and CD8[+] T cells (E) in the BM
between pediatric AML patients and non-leukemic controls. (F-G) Normalized abundance of
CD3[+] T cells (F) and CD8[+] T cells (G) per cytogenetic pediatric AML subgroup. 'Normal'
indicates normal karyotype, while 'Others' is a merge of cytogenetic abnormalities different
from the four defined cytogenetic subgroups.

Figure 2. Transcriptional differences between immune-infiltrated and immune-
depleted pediatric AML samples.

(A) Volcano plot of differentially expressed genes between immune-infiltrated and immune-
depleted pediatric AML BM samples, identified using *DEseq2* with an FDR cut-off of 0.05
and minimum fold change (FC) of 2. (B) Parametric gene set enrichment analysis of
differentially expressed genes between immune-infiltrated (orange) and immune-depleted
samples (blue) using the GO Biological Processes gene set with an FDR cut-off of 0.05.
Values in front of the biological processes indicate *P* values. (C) Correlation plot of the
inverse correlation between the M2-like macrophage abundance and the normalized number
of CD3[+] T cells, calculated using Spearman correlation. (D-E) Comparison of the M2-like
macrophage abundance between immune-infiltrated (n=5) and immune-depleted (n=18) BM
samples (D) and between BM samples of refractory or relapsed (R/R) adult AML patients
with anti-leukemic activity (ALA) or non-responders (NR) to treatment with the bispecific
antibody flotetuzumab (E). (F) Area under the receiver operating characteristic curves
measuring the predictive ability of the M2-like macrophage abundance (black), T cell
inflamed gene expression profile (GEP; pink), CD8 score (blue), IFN-*γ* score (green), and
the tumor immune dysfunction and exclusion score (TIDE; orange) in pre-treatment R/R
adult AML samples for response to flotetuzumab.

Figure 3. Immune-infiltrated pediatric AML samples harbor an increased abundance of
spatially organized T cell networks.

(A) Illustration of the identification of directly interacting T cells (above) and T cell networks
(below) using Delaunay Triangulation. (B) Comparison of the normalized abundance of T cell

networks between immune-infiltrated, immune-depleted, and non-leukemic control samples.

(C) Correlation plot of the positive correlation between the normalized number of CD3$^+$ T

cells and the normalized number of T cell networks in both AML and non-leukemic control

samples (n=53), calculated using Spearman correlation. (D) Comparison of the average

number of T cells in a network between immune-infiltrated, immune-depleted, and non-

leukemic control samples. (E-F) Representative images of an immune-infiltrated pediatric

AML BM sample with multiple large T cell clusters (>100 T cells; CD3 in brown; E) that are

largely devoid of AML cells (CD117 in brown, patient-specific AML immunophenotypic

marker; F). (G-H). Representative images of an immune-depleted pediatric AML BM sample

without T cell clusters (CD3 in brown; G) and widely dispersed AML cells (CD117 in brown;

patient-specific AML immunophenotypic marker; H).

Figure 4. Spatial transcriptomics reveals gene expression characteristics of tertiary

lymphoid structures in *KMT2A*-rearranged immune-infiltrated pediatric AML samples.

(A-C) Images of the bone biopsy sections that show the expression levels of a previously

published TLS-signature in distinct regions of two lymphoid aggregate (LA)-positive (A+B)

KMT2A-rearranged immune-infiltrated pediatric AML samples and one LA-negative (C)

KMT2A-rearranged immune-infiltrated pediatric AML sample, next to immunohistochemistry-

based images of CD3$^+$ T cells, CD20$^+$ B cells, and CD117$^+$ (A+C) or CD4$^+$ (B) AML cells.

Orange arrows indicate LA-containing regions.

Figure 5. Spatial deconvolution identifies localized cellular and humoral immunity in

***KMT2A*-rearranged immune-infiltrated pediatric AML samples.**

(A) Dendrogram and bar plot of absolute immune- and stromal-cell abundance scores,

calculated by applying the *SpatialDecon* algorithm to spatial transcriptomic data from three

KMT2A-rearranged immune-infiltrated pediatric AML BM samples. Regions are divided in

separate clusters based on similarity (unsupervised hierarchical clustering; Euclidian

distance; complete linkage). The legend on the right indicates which type of cell is shown in

the bar plot and for which type of region the cell composition is shown. (B-K) Comparisons of

the abundance scores of several immune- and stromal cell types between mixed regions

(n=48), T cell network regions (n=26), and TLS-like aggregate regions (n=20). Tregs

indicates regulatory T cells, and DCs indicate dendritic cells. (I) Whole-slide bone biopsy

image with a CD3 stain (brown) for T cells (above), and a magnified image illustrating the

presence of IgM$^+$- (brown) and IgG$^+$-cells (purple) in the T cell rich area that is part of an

TLS-like aggregate. (M) Magnifications of the T cell rich area shown in the whole-slide image

shown in Figure I, showing the presence of CD11c$^+$ CD68/CD163$^+$ macrophages (red

arrows) in the TLS-like aggregate region.

Extended Data Figure 1. Cell-type specific gene expression of immune checkpoint

genes in pediatric AML.

(A) UMAP of cell populations identified in BM samples from 8 newly diagnosed pediatric

AML patients using scRNAseq by Bailur et al. (B-E) Cell-type specific expression of *PDCD1*

(B), *CTLA4* (C), *TIGIT* (D), *LAG3* (E) in the scRNAseq dataset. (F) Correlation plot of the

inverse correlation between the M2-like macrophage abundance and the normalized number

of CD8$^+$ T cells, calculated using Spearman correlation. CD8Tex: exhausted cytotoxic T

cells; CD8Tem: effector memory cytotoxic T cells; cDC1: conventional dendritic cells type I;

EryPro: erythroid progenitors; M1: M1-like macrophages.

Extended Data Figure 2. Region-specific gene expression and deconvoluted cell type

abundance in the bone marrow of *KMT2A*-rearranged pediatric AML.

(A) Volcano plot of differentially expressed genes between TLS-like aggregate regions and

mixed regions, identified using a linear mixed-effects model including random slope and the

FDR method. FC indicates fold change. (B-D) Comparisons of the ratio between activated

and resting cytotoxic T cells (B), the abundance scores of plasmacytoid dendritic cells (C),

and neutrophils (D) between mixed regions (n=48), T cell network regions (n=26), and TLS-

like aggregate regions (n=20).

Index of supplemental tables

Extended Data Table 1. Patient characteristics from 43 treatment-naïve pediatric patients

with AML and 10 non-leukemic controls.

Extended Data Table 2. Number of T cell networks and TLS-like aggregates for each
patient.

Extended Data Table 3. Antibodies used for immunohistochemistry of bone biopsy tissue.

Extended Data Table 1. Patient characteristics from 43 treatment-naïve pediatric patients
with AML and 10 treatment-naïve non-leukemic controls.

ID	Sex	%BM Myelo-blasts	FAB	Cytogenetic alterations	Molecular aberrations	Immune infiltration	GEP + Spatial Tx
AML1	male	32	M2	NA	NA	Infiltrated	GEP
AML2	female	51	M5	KMT2Ar	none	Infiltrated	GEP + Spatial Tx
AML3	male	NA	NA	KMT2Ar	none	Infiltrated	GEP
AML4	male	55	NA	KMT2Ar	none	Infiltrated	GEP
AML5	male	28	NA	KMT2Ar, Trisomy-8	none	Infiltrated	Spatial Tx
AML6	male	44	NA	KMT2Ar	none	Infiltrated	GEP + Spatial Tx
AML7	male	39	NA	inv(16)	none	Infiltrated	
AML8	male	81	NA	t(8;21), 8q-deletion, Y-chromosome deletion	EXT1mut + RAD21mut	Infiltrated	
AML9	male	63	NA	KMT2Ar	none	Depleted	
AML10	male	81	NA	KMT2Ar	none	Depleted	
AML11	male	73	M5	inv(16)	none	Depleted	
AML12	male	77	M2	t(8;21)	none	Depleted	GEP
AML13	female	NA	NA	Normal karyotype	NPM1mut + WT-1mut	Depleted	GEP
AML14	male	50	M2	t(8;21)	none	Depleted	
AML15	female	14	M6	NA	NA	Depleted	
AML16	male	88	M1	t(8;21)	none	Depleted	GEP
AML17	female	31	M0	Normal karyotype	none	Depleted	
AML18	male	10	M7	NA	NA	Depleted	
AML19	male	NA	M5	NA	NA	Depleted	
AML20	female	NA	M6	NA	NA	Depleted	

AML21	female	72	M4	Monosomy-7	none	Depleted	GEP
AML22	male	94	M5	KMT2Ar	none	Depleted	GEP
AML23	male	98	M5	KMT2Ar	none	Depleted	GEP
AML24	female	20	NA	NA	NA	Depleted	GEP
AML25	male	8	M7	Trisomy-8	none	Depleted	GEP
AML26	male	80	M5	KMT2Ar	none	Depleted	GEP
AML27	male	36	M2	t(8;21)	WT-1mut	Depleted	GEP
AML28	female	69	NA	KMT2Ar	none	Depleted	GEP
AML29	male	45	M2	NA	NA	Depleted	GEP
AML30	male	39	M2	NA	NA	Depleted	GEP
AML31	female	NA	NA	NA	NA	Depleted	
AML32	female	38	NA	inv(16)	none	Depleted	GEP
AML33	female	34	NA	Normal karyotype	NPM1mut	Depleted	GEP
AML34	male	NA	NA	Normal karyotype	FLT3-ITDmut	Depleted	GEP
AML35	male	92	M5	KMT2Ar	none	Depleted	
AML36	female	90	M5	KMT2Ar	none	Depleted	
AML37	male	32	NA	9q-deletion	none	Depleted	
AML38	male	18	NA	Normal karyotype	none	Depleted	
AML39	male	0	NA	Normal karyotype	NPM1mut	Depleted	
AML40	male	12	NA	t(6;9)	WT1mut + NRASmut	Depleted	
AML41	female	5	NA	t(5;11)	none	Depleted	
AML42	male	63	NA	Monosomy-7, gain chromosome -13	TP53mut, RUNX1mut, SUZ12mut	Depleted	GEP
AML43	male	92	M5	KMT2Ar	NRASmut	Depleted	GEP
CTRL1	male	1	Not applicable				
CTRL2	female	0	Not applicable				
CTRL3	female	1	Not applicable				
CTRL4	male	2	Not applicable				
CTRL5	female	3	Not applicable				

CTRL6	male	1	Not applicable
CTRL7	male	1	Not applicable
CTRL8	male	0	Not applicable
CTRL9	male	2	Not applicable
CTRL1 0	female	1	Not applicable

AML: acute myeloid leukemia; BM: bone marrow; CTRL: non-leukemic control; dx: diagnosis; FAB: French-American-British (classification); GEP: gene expression profiling; KMT2Ar: KMT2A-rearranged; mut: mutation; NA: not available; Spatial Tx: spatial transcriptomics.

Extended Data Table 2. Number of T cell networks and TLS-like aggregates for each patient.

		T cell network number (by size)				
ID	Immune infiltration	10-30 cells	31-99 cells	100-500 cells	>500 cells	TLS-like aggregates
AML1	Infiltrated	161	30	11	1	NA
AML2	Infiltrated	191	57	15	8	6
AML3	Infiltrated	473	62	11	0	11
AML4	Infiltrated	92	11	1	0	1
AML5	Infiltrated	22	1	0	0	0
AML6	Infiltrated	320	48	7	1	4
AML7	Infiltrated	138	2	0	0	0
AML8	Infiltrated	18	0	0	0	0
AML9	Depleted	541	61	0	0	0
AML10	Depleted	242	9	0	0	0
AML11	Depleted	0	0	0	0	0
AML12	Depleted	0	0	0	0	0
AML13	Depleted	1	1	0	0	0
AML14	Depleted	0	0	0	0	0
AML15	Depleted	5	0	0	0	0
AML16	Depleted	3	0	0	0	0
AML17	Depleted	3	0	0	0	0
AML18	Depleted	1	0	0	0	0
AML19	Depleted	0	0	0	0	0
AML20	Depleted	3	0	0	0	0
AML21	Depleted	0	0	0	0	0
AML22	Depleted	6	0	0	0	0
AML23	Depleted	29	0	0	0	0
AML24	Depleted	82	4	1	0	NA
AML25	Depleted	4	0	0	0	0
AML26	Depleted	1	0	0	0	0
AML27	Depleted	1	0	0	0	0
AML28	Depleted	30	0	0	0	0
AML29	Depleted	8	1	0	0	0
AML30	Depleted	10	0	1	0	1
AML31	Depleted	6	0	0	0	0

AML32	Depleted	0	0	0	0	0
AML33	Depleted	0	0	0	0	0
AML34	Depleted	7	0	0	0	0
AML35	Depleted	27	1	0	0	0
AML36	Depleted	0	0	0	0	0
AML37	Depleted	2	1	0	0	0
AML38	Depleted	0	0	0	0	0
AML39	Depleted	19	1	0	0	0
AML40	Depleted	5	0	0	0	0
AML41	Depleted	51	7	0	0	0
AML42	Depleted	58	3	0	0	0
AML43	Depleted	74	7	1	0	NA
CTRL1	Control	11	0	0	0	0
CTRL2	Control	3	0	0	0	0
CTRL3	Control	8	0	0	0	0
CTRL4	Control	88	5	0	0	0
CTRL5	Control	62	5	0	0	0
CTRL6	Control	29	5	0	0	0
CTRL7	Control	63	0	0	0	0
CTRL8	Control	19	0	0	0	0
CTRL9	Control	46	1	0	0	0
CTRL10	Control	34	3	0	0	0

684   AML: acute myeloid leukemia; CTRL: non-leukemic control; TLS: tertiary lymphoid structure;

685   NA: the presence of TLS-like aggregates could not be assessed in these biopsies since a

686   CD20[+] B cell stain was lacking.

Koedijk et al.

688   **Extended Data Table 3.** Antibodies used for immunohistochemistry of bone biopsy tissue.

Antibody	Code	Supplier	Catalog No.	Dilution
CD3	2GV6	Roche	05278422001	NA
CD4	SP35	Roche	05552737001	NA
CD8	SP57	Roche	5973248001	NA
CD20	L26	Roche	5267099001	NA
CD15	MMA	Roche	5266904001	NA
CD34	QBEnd/10	Roche	6389320001	NA
CD117	EP10	Roche	790-7061	NA
IgM	GA513	Dako	GA51361-2	1:24.000
IgG	GA512	Dako	GA51261-2	1:60.000

689   NA: Not applicable.

Figure 1

B Acute Myeloid Leukemia

H&E   CD3   CD8

C Non-leukemic Control

H&E   CD3   CD8

D Mann-Whitney, $P = 0.006$

E Mann-Whitney, $P = 0.003$

F Kruskal-Wallis, $P = 0.16$

G Kruskal-Wallis, $P = 0.438$

Figure 2

Figure 3

A

Direct contact

≤ 10 μm

T cell network

≥ 10 T cells in direct contact

B

Kruskal-Wallis, $P < 0.001$

< 0.001

T cell networks / 10 cm^2

Infiltrated (N=11) Depleted (N=33) Controls (N=10)

C

$r = 0.86$
$P < 0.001$

T cell networks / 10 cm^2

CD3+ cells/mm^2

D

Kruskal-Wallis, $P = 0.06$

0.086

Average number of T cells in network

Infiltrated (N=11) Depleted (N=25) Controls (N=10)

E

Immune-Infiltrated sample

600 μm

CD3

F

600 μm

CD117

G

Immune-depleted sample

600 μm

CD3

H

600 μm

CD117

Figure 4

A

LA-positive

TLS Signature   CD3   CD20   CD117

B

LA-positive

TLS Signature   CD3   CD20   CD3-CD4

C

LA-negative

TLS Signature   CD3   CD20   CD117

Figure 5

A

Abundance scores

Cell
- fibroblasts
- endothelial.cells
- Treg
- neutrophils
- monocytes.NC.I
- monocytes.C
- mDCs
- pDCs
- NK
- T.CD8.memory
- T.CD8.naive
- T.CD4.memory
- T.CD4.naive
- plasma
- B.memory
- B.naive
- mast
- macrophages

Annotation
- mixed
- T cell network
- TLS-like aggregate

B Memory cytotoxic T cells — Kruskal-Wallis, $P < 0.001$; < 0.001; < 0.001 — Abundance score — Mixed, T cell network, TLS-like

C Tregs — Kruskal-Wallis, $P < 0.001$; < 0.001; < 0.001 — Abundance score — Mixed, T cell network, TLS-like

D Activated CD8$^+$ T cells — Kruskal-Wallis, $P < 0.001$; < 0.001; 0.024 — Abundance score — Mixed, T cell network, TLS-like

E Resting CD8$^+$ T cells — Kruskal-Wallis, $P < 0.001$; < 0.001; 0.0014 — Abundance score — Mixed, T cell network, TLS-like

F Naive B cells — Kruskal-Wallis, $P < 0.001$; < 0.001; < 0.001 — Abundance score — Mixed, Others, TLS-like

G Memory B cells — Kruskal-Wallis, $P < 0.001$; < 0.001; < 0.001 — Abundance score — Mixed, T cell network, TLS-like

H Plasma cells — Kruskal-Wallis, $P < 0.001$; < 0.001; 0.0015 — Abundance score — Mixed, T cell network, TLS-like

I Myeloid DCs — Kruskal-Wallis, $P = 0.0029$; 0.0042 — Abundance score — Mixed, T cell network, TLS-like

J Macrophages — Kruskal-Wallis, $P < 0.001$; < 0.001; < 0.001 — Abundance score — Mixed, T cell network, TLS-like

K M2-like macrophages — Kruskal-Wallis, $P < 0.001$; < 0.001; < 0.001 — Abundance score — Mixed, T cell network, TLS-like

I
800 μm
CD3
60 μm
IgM & IgG

M
100 μm
CD20 & CD11c & CD68/CD163
20 μm
20 μm

Extended Data Figure 1

Extended Data Figure 2